Intra-Cellular Therapies, Inc. 23I.F Stock
Intra-Cellular Therapies, Inc. Price Chart
Intra-Cellular Therapies, Inc. 23I.F Financial and Trading Overview
| Intra-Cellular Therapies, Inc. stock price | 60 EUR |
| Previous Close | 58.7 EUR |
| Open | 58 EUR |
| Bid | 58.2 EUR x 20000 |
| Ask | 59.6 EUR x 20000 |
| Day's Range | 58 - 58 EUR |
| 52 Week Range | 40.2 - 61.5 EUR |
| Volume | 45 EUR |
| Avg. Volume | 10 EUR |
| Market Cap | 5.59B EUR |
| Beta (5Y Monthly) | 1.126408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.4 EUR |
23I.F Valuation Measures
| Enterprise Value | 5.18B EUR |
| Trailing P/E | N/A |
| Forward P/E | -23.67347 |
| PEG Ratio (5 yr expected) | -0.05 |
| Price/Sales (ttm) | 17.983465 |
| Price/Book (mrq) | 8.842812 |
| Enterprise Value/Revenue | 16.669 |
| Enterprise Value/EBITDA | -21.688 |
Trading Information
Intra-Cellular Therapies, Inc. Stock Price History
| Beta (5Y Monthly) | 1.126408 |
| 52-Week Change | 17.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 61.5 EUR |
| 52 Week Low | 40.2 EUR |
| 50-Day Moving Average | 55.68 EUR |
| 200-Day Moving Average | 49.31 EUR |
23I.F Share Statistics
| Avg. Volume (3 month) | 10 EUR |
| Avg. Daily Volume (10-Days) | 23 EUR |
| Shares Outstanding | 95.93M |
| Float | 93.64M |
| Short Ratio | N/A |
| % Held by Insiders | 2.59% |
| % Held by Institutions | 93.95% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -73.46% |
| Operating Margin (ttm) | -77.057% |
| Gross Margin | 46.00% |
| EBITDA Margin | -76.85% |
Management Effectiveness
| Return on Assets (ttm) | -18.80% |
| Return on Equity (ttm) | -32.13% |
Income Statement
| Revenue (ttm) | 310.62M EUR |
| Revenue Per Share (ttm) | 3.28 EUR |
| Quarterly Revenue Growth (yoy) | 172.30% |
| Gross Profit (ttm) | 95.16M EUR |
| EBITDA | -238736992 EUR |
| Net Income Avi to Common (ttm) | -228190000 EUR |
| Diluted EPS (ttm) | -2.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 538.71M EUR |
| Total Cash Per Share (mrq) | 5.62 EUR |
| Total Debt (mrq) | 18.49M EUR |
| Total Debt/Equity (mrq) | 2.95 EUR |
| Current Ratio (mrq) | 8.872 |
| Book Value Per Share (mrq) | 6.559 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -247403008 EUR |
| Levered Free Cash Flow (ttm) | -170029504 EUR |
Profile of Intra-Cellular Therapies, Inc.
| Country | Germany |
| State | NY |
| City | New York |
| Address | 430 East 29th Street |
| ZIP | 10016 |
| Phone | 646 440 9333 |
| Website | https://www.intracellulartherapies.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 561 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Q&A For Intra-Cellular Therapies, Inc. Stock
What is a current 23I.F stock price?
Intra-Cellular Therapies, Inc. 23I.F stock price today per share is 60 EUR.
How to purchase Intra-Cellular Therapies, Inc. stock?
You can buy 23I.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Intra-Cellular Therapies, Inc.?
The stock symbol or ticker of Intra-Cellular Therapies, Inc. is 23I.F.
Which industry does the Intra-Cellular Therapies, Inc. company belong to?
The Intra-Cellular Therapies, Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Intra-Cellular Therapies, Inc. have in circulation?
The max supply of Intra-Cellular Therapies, Inc. shares is 105.57M.
What is Intra-Cellular Therapies, Inc. Price to Earnings Ratio (PE Ratio)?
Intra-Cellular Therapies, Inc. PE Ratio is now.
What was Intra-Cellular Therapies, Inc. earnings per share over the trailing 12 months (TTM)?
Intra-Cellular Therapies, Inc. EPS is -1.07 EUR over the trailing 12 months.
Which sector does the Intra-Cellular Therapies, Inc. company belong to?
The Intra-Cellular Therapies, Inc. sector is Healthcare.